Since PGD2 is known to have both PTGDR-dependent and independent pro- and anti-inflammatory roles48, direct PGD2 synthesis inhibition may not be a safe therapeutic approach in human SLE. The gene discussed is HPGDS; the disease is systemic lupus erythematosus.